Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
13 participants
OBSERVATIONAL
2012-04-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The Cobb angle measurement of scoliosis represents the sum of the angular wedging of each vertebra and disc between the superior and inferior end vertebrae . Although a small curve is well tolerated and does not require treatment, a large curve can progress to the point that it is cosmetically unacceptable, interferes with chest wall mechanics, and produces cardiac and pulmonary compromises. The natural history of AIS apparently includes 2 stages: the initiation of the curve and its subsequent progression. The factors responsible for the initiation of the curve are unknown, but the subsequent progression of the curve is clearly associated with the adolescent growth spurt . The primary risk factors for progression include age at onset and the magnitude of the curve; young patients with large curves are at the highest risk .
Although numerous treatment methods have been recommended for patients with AIS, the only accepted treatment includes bracing for skeletally immature patients with curves between 25 and 40 degrees and operative correction with spinal fusion for patients with curves greater than 45 degrees. For many teenagers, the cosmetic and social concerns associated with bracing has caused compliance problems with wearing the brace and many patients only wear the brace at home . While operative intervention completely corrects the scoliosis or rib hump, it eliminates segmental spinal motion, and concentrates stresses at the ends of the fusion potentially leading to disc degeneration and back pain.
Despite satisfactory short-term results of operative instrumentation and fusion, a less invasive technique preserving more motion with a smaller scar represents a major improvement. Realizing this goal is contingent on treating curves early, before they progress to an irreversible deformity, and when there is still enough residual growth and remodeling potential.
ApiFix Ltd has developed a novel implant for less invasive treatment of AIS. The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues time to accommodate any incremental correction.
The MID-C System inherent benefits are:
* Only two screws are used
* Incision size is much smaller
* Simpler operation with shorter operative time
* Less complications (attributed to the three points above).
* Minimal spinal mobility loss.
All the device components are made of materials well accepted in the orthopedic field and are fully biocompatible (see Investigator Brochure).
The unique concept of the system and the materials used may provide favorable results as follows: Smaller scare, quicker healing period and better spine mobility over the years.
This study is designed to demonstrate that the MID-C System is safe and effective.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility Evaluation Study of the MID-C Device
NCT03071471
Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)
NCT02200302
PMS Evaluation of Safety and Efficacy of the MID-C System 5 Years Post-implantation in AIS
NCT04684927
Post-approval Registry Study to Evaluate the Continued Safety and Probable Benefit of the MID-C System for 5 Years Post-Implantation in Adolescent Idiopathic Scoliosis (AIS)
NCT04296903
Minimal Invasive Deformity Correction (MID-C) System for Early Onset Scoliosis
NCT03519321
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Minimum of 35 degrees Cobb angle, confirmed by X-ray. Lenke type 1 or 5
3. Completed at least 6 months of conservative therapy (e.g., P.T., bracing, traction, or others).
4. Reisser sign of 2 to 4
5. Appropriate candidate for posterior surgical approach
6. Subject has Good general health.
7. Subject has no hypersensitivity and allergies to Titanium
8. Subject guardians willing to sign a written informed consent form (ICF).surgeon
Exclusion Criteria
2. Other non idiopathic scoliosis.
3. AIS which is not defined as Lenke type 1 or 5
4. Previous spine surgery.
5. Allergy to any component of the device.
6. Active systemic disease, such as AIDS, HIV, or active infection
7. Back or leg pain of unknown etiology
8. Systemic disease that would affect the subject's welfare or overall outcome of the study.
9. Mentally compromised
11 Years
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Apifix
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sergiu Straticiuc-ciongradi, MD
Role: PRINCIPAL_INVESTIGATOR
Spitalul de Copii Sf. Maria Lasi
Peter Than, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pecs Medical School Hungary
Gheorghe Burnei, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Maria Sklodowska Curie, Bucharest
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pecs
Pécs, , Hungary
Spitalul de Copii Sf. Maria
Iași, Romania, Romania
Maria Sklodowska Curie
Bucharest, , Romania
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AF-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.